Education
About Us
Working with TipRanks
Follow Us
Shield Therapeutics PLC (GB:STX)
LSE:STX
STX Stock Chart & Stats
Day’s Range― - ―
52-Week Range1.50p - 5.87p
Previous CloseN/A
Volume699.61K
Average Volume (3M)1.81M
Market Cap
£24.48M
Enterprise ValueN/A
Total Cash (Recent Filing)£5.61M
Total Debt (Recent Filing)£21.06M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Sep 04, 2025EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,041,690,400
10 Day Avg. Volume854,887
30 Day Avg. Volume1,814,937
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-18.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£3.80Price Target Upside61.70% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Shield Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Financial Support$6.5m of cash plus successful $10m raise with AOP Health does provide some much-needed breathing room for Shield in 2025.
Revenue GrowthShield's 2024 trading update sees the company expect to deliver $32.2m of revenues for 2024, driven primarily by US Accrufer sales which grew 153%.
Bears Say
Cash Flow ConcernsStrong sales growth for Accrufer is still required to achieve the goal of cashflow breakeven, and funding does remain tight.
Prescription VolumeThe increase in NSP offsets a 6% decrease in prescription volumes QoQ, a significant slowdown vs Q2 and Q3 which delivered more than 20% prescription growth.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.06% Insiders
―
Mutual Funds
― Other Institutional Investors
99.94% Public Companies and
Individual Investors
STX FAQ
What was Shield Therapeutics PLC’s price range in the past 12 months?
Shield Therapeutics PLC lowest share price was 1.50p and its highest was 5.87p in the past 12 months.
What is Shield Therapeutics PLC’s market cap?
Shield Therapeutics PLC’s market cap is £24.48M.
When is Shield Therapeutics PLC’s upcoming earnings report date?
Shield Therapeutics PLC’s upcoming earnings report date is Sep 04, 2025 which is in 108 days.
How were Shield Therapeutics PLC’s earnings last quarter?
Shield Therapeutics PLC released its earnings results on Apr 24, 2025. The company reported -0.011p earnings per share for the quarter, beating the consensus estimate of -0.013p by 0.002p.
Is Shield Therapeutics PLC overvalued?
According to Wall Street analysts Shield Therapeutics PLC’s price is currently Undervalued.
Does Shield Therapeutics PLC pay dividends?
Shield Therapeutics PLC does not currently pay dividends.
What is Shield Therapeutics PLC’s EPS estimate?
Shield Therapeutics PLC’s EPS estimate is -1.13.
How many shares outstanding does Shield Therapeutics PLC have?
Shield Therapeutics PLC has 1,041,690,400 shares outstanding.
What happened to Shield Therapeutics PLC’s price movement after its last earnings report?
Shield Therapeutics PLC reported an EPS of -0.011p in its last earnings report, beating expectations of -0.013p. Following the earnings report the stock price went down -3.83%.
Which hedge fund is a major shareholder of Shield Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:STX
---
Shield Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£3.80 (61.70% Upside)
£3.80 (61.70% Upside)
Insider Transactions
Bought Shares
Worth £21.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.02%
12-Months-Change
Fundamentals
Return on Equity
-396.71%
Trailing 12-Months
Asset Growth
19.90%
Trailing 12-Months
Company Description
Shield Therapeutics PLC
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
---
STX Stock 12 Month Forecast
Average Price Target
3.80p
▲(61.70% Upside)
Technical Analysis
Allergy Therapeutics
―
Alliance Pharma
―
Animalcare
―
Hikma Pharmaceuticals
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
---